About Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aims to harness, direct and optimize their immune suppressive ...

Regulatory T cells (Tregs) have gone from obscurity to rock-star status in the past decade, prompting intense scrutiny—but what exactly are they? Four studies examine this question, delving ...

Taiwan’s REGiMMUNE and Europe-based Kiji Therapeutics are merging to create a globally minded regulatory T-cell biotech that ...

Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and ...

Northwestern Medicine scientists have discovered a new mechanism that controls a specialized group of T-cells, known as ...

This important study provides solid in-vivo evidence that CCR4 regulates the early inflammatory response during atherosclerotic plaque formation. The authors propose that altered T-cell response plays ...

Quell Therapeutics Ltd (“Quell” or “the Company”), and eXmoor pharma (“eXmoor”), announce a strategic partnership for the manufacture of multiple autologous engineered CAR-Treg cell therapies in Quell ...

Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate development New CAR-Treg cell therapy ...

London, UK and Bristol, UK, 24 September 2024 – Quell Therapeutics Ltd (“Quell” or “the Company”), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical ...